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Abstract
Micro-RNAs (miRs) are important regulators of mRNA and protein expression; the ability of miR expression
profilings to distinguish different cancer types and classify their sub-types has been well-described. They also
represent a novel biological entity with potential value as tumour biomarkers, which can improve diagnosis,
prognosis, and monitoring of treatment response for human cancers. This endeavour has been greatly facilitated
by the stability of miRs in formalin-fixed paraffin-embedded (FFPE) tissues, and their detection in circulation. This
review will summarize some of the key dysregulated miRs described to date in human epithelial malignancies, and
their potential value as molecular bio-markers in FFPE tissues and blood samples. There remain many challenges in
this domain, however, with the evolution of different platforms, the complexities of normalizing miR profiling data,
and the importance of evaluating sufficiently-powered training and validation cohorts. Nonetheless, well-conducted
miR profiling studies should contribute important insights into the molecular aberrations driving human cancer
development and progression.
Introduction
Micro-RNAs (miRs) are important regulators of mRNA
and protein expression which play important yet com-
plex roles in human cancers [1]. Their biogenesis and
biological networks are complex (Figure 1); they are first
synthesized as large RNA precursors, processed in the
nucleus into approximately 70 nt pre-miRs, folded into
imperfect stem-loop structures, transported to the cyto-
plasm, whereupon they are incorporated into RISC
(RNA-induced silencing complex) (reviewed in [2]).
Cleavage by Argonaute-2, then Dicer, results in an
approximately 22-nt mature miR duplex; the “guide”
strand is retained within the RISC; the “passenger”
strand is degraded. Through the seed region (nt 2 to 8),
t h em i Rc a nt h e nb i n dt ot h e3 ’UTR of target mRNA
sequences, preventing protein translation, leading to
mRNA degradation. More recently, miRs have also been
described to target 5’UTR, and even coding regions of
transcripts [3]. The current miRDatabase (http://www.
mirbase.org) has catalogued more than 1,300 human
sequences. Given their ability to target mRNA with
imperfect complementarity, and predicted to regulate
the expression of approximately one-third of all human
transcripts [4], miRs are considered to be among the lar-
gest class of gene regulators [5,6].
Multiple mechanisms can mediate miR dysregulations
in human cancers, including chromosomal gains or
losses [7], mutations of miR located loci [8], or epige-
netic aberrations [8]. Any misstep in miR biogenesis
(Figure 1) can also affect miR expression [9,10], exem-
plified by the down-regulation of Drosha and Dicer
being associated with worse survival in ovarian, lung,
and breast cancers [11]. MiRs can be either over- or
under-expressed, functioning as tumour suppressors or
oncogenes, depending on their downstream target genes
[12]. MiR-15a and miR-16-1 are two of the first
described down-regulated miRs in chronic lymphocytic
leukemia [13], both target Bcl-2 [14]; thus their absence
inhibits apoptosis. Alternatively, miR-21, one of the
most commonly over-expressed miRs in solid malignan-
cies, targets PTEN [15] and pro-apoptotic genes [16,17];
hence pro-survival signals dominate.
Micro-RNA as bio-markers in epithelial cancers
Biomarkers are biological indicators of disease states,
utilized to define tumor subtypes, or assess efficacy of
interventions [18]. Useful biomarkers can provide
insights into tumorigenesis, and facilitate the
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markers include prostate-specific antigen (PSA) [19],
carcinoembryonic antigen (CEA) [20], CA125 [21], and
a-fetoprotein [22,23]. More recently, the role of
mRNA or miRs as cancer biomarkers have also been
investigated and developed. The prototype mRNA sig-
nature is Oncotype DX, the 21-gene set utilized to
predict recurrence risks for patients with breast cancer
[24].
MiR expression profilings could distinguish different
cancer types [12], classify sub-types of prostate or breast
cancers [25], identify the tissue origin of tumors [26],
and facilitate the diagnosis of colon [27], or lung cancers
[28]. MiRs can also predict outcome, such as let-7a [28]
Figure 1 Micro-RNA biogenesis. MiR’s are synthesized initially as large RNA precursors (pri-miRs), processed in the nucleus by RNAse III Drosha,
and DGCR8 into approximately 70 nt pre-miR, which are transported to the cytoplasm by exportin-5, with subsequent cleavage by another
RNAse III enzyme Dicer, with its co-factor TRBP, releasing the approximately 22-nt mature dsmiR. MiR’s can negatively regulate their targets in
one of two major ways, depending on the degree of complementarity to its target. First, and probably most commonly, one strand of this
duplex is incorporated into the RNA-induced silencing complex (RISC), then binds with imperfect complementarity to the 3’-UTR (untranslated
region) of mRNA targets, preventing protein translation. Alternatively, miRs can bind with perfect complementarity to the ORF (open reading
frame) of target mRNA’s with subsequent degradation. Recent evidence also indicates miRs can also bind to either promoters, or coding regions
of mRNAs as additional mechanisms of regulation.
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Page 2 of 9and miR-155 [29] for lung cancer, and select patients for
targeted therapy (for example, breast cancer [30]).
Finally, predictive miR signatures have been reported for
several malignancies, such as lung [31-34], hepatocellu-
lar [35], esophageal [36], gastric [37], prostate [38] cervi-
cal [39], and colon cancers [40].
Micro-RNAs in FFPE samples
The ability to examine FFPEspecimens, a universally
standard histologic processing procedure, allows the
expeditious discovery and evaluation of potential bio-
markers, given their possible link to clinical databases
with mature follow-up. Transcript (mRNA) profiling is
technically challenging with FFPE samples due to signifi-
cant RNA degradation during formalin fixation [41,42],
and continued deterioration with storage over time [43].
In contrast, miRs are not significantly affected by fixa-
tion, and can be readily extracted from FFPE samples
due to their small sizes (approximately 22 nt in length)
and remarkable stability [44,45]. Hence, this greatly
enhances the ability to evaluate miRs as cancer biomar-
kers, leading to a multitude of reports describing miR
expressions in many epithelial malignancies, summar-
ized as per anatomical site in Table 1.
As already mentioned, miR-21 up-regulation is the
most commonly observed aberrant miR in human can-
cers, with oncogenic consequences [46] (Table 1). It was
first reported in glioblastoma [16], but also described for
epithelial cancers such as head and neck, breast, colon,
lung, prostate, and others [12,44,47]; often associated
with worse outcome [40]. Over-expression of miR-21
has been shown to increase cell proliferation, migration,
invasion and survival [48]; in contrast, suppression of
miR-21 induced apoptosis and decreased cell prolifera-
tion and invasion [49].
Mir-155 is another commonly dysregulated miR,
wherein the majority of studies report its over-expres-
sion associated with tumorigenesis in lymphomas,
breast, lung, colon, pancreatic cancers, and others [50].
Aside from these two miRs, there is usually minimal
overlap of dysregulated miRs described amongt different
studies, even when examining the same cancer type; the
same variation as previously observed for mRNA profil-
ing. Perhaps this might relate to multiple redundant
Table 1 Micro-RNAs as Diagnostic or Prognostic markers in FFPE Samples
Cancer Diagnostic miRs Prognostic miRs References
Head and Neck Squamous cell carcinoma miR-16, -20a, -21, -106b, -142-3p, -155, -423, let-7i (up);
miR-10a, -125b, -375 (down)
miR-451 (up) [47]
Breast cancer miR-21(up); let-7a, miR-145, -205 (down) [70]
miR-21 (up) [71]
miR-21, -155, -191, -196a (up); miR-125b, -221 (down) [44]
Lung cancer miR-21, -205 [72]
miR-16 (up) [73]
Gastrointestinal Cancers
Gastric cancer miR-106a (up) [74]
miR-31 (down) [75]
miR-10b, -21, -223, -338 (up);
miR-30a-5p,
-126, let-7a (down)
[37]
Pancreatic cancer miR-452, -105, -127, -518a-2, -187, -30a-3p (up) miR-196a-2 (up) [76]
miR-21, -155 (up) [77]
miR-21, -221, -222, let-7a (up) [78]
miR-200c (down) [79]
Gynecological Cancers
Cervical cancer miR-9, -200a [39]
Ovarian cancer miR-223 (up); miR-9 (down) [80]
miR-200a, -200b, -429 (down) [81]
miR-23a, -27a (up) [82]
miR-29b (up) [83]
Prostate cancer miR-125b (up) [84]
miR-15a, -16 (down) [85]
miR-184 (up); miR-146a (down) miR-184 (up) [86]
miR-203 (down) [87]
miR-34c (down) miR-34c (down) [88]
miR-221 (down) [89]
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Page 3 of 9Table 2 Micro-RNAs as Non-invasive Biomarkers in Blood Samples
Cancer Samples Diagnostic miRs Prognostic miRs References
Head and Neck Plasma miR-184 (up) [90]
Squamous cell
carcinoma
Plasma miR-24 (up) [91]
Plasma miR-31 (up) [92]
Plasma miR-181 (up) miR-181 (up) correlated with poor survival,
lymph-node metastasis, and vascular invasion
[93]
Breast cancer Serum miR-155 (up) in PR+ve patients [68]
Plasma miR-425*(up);
let-7d*(down)
[94]
Serum miR-10b, -34a, -155 (up) miR-10b, -34a, -155 (up) correlated with
metastasis
[95]
Serum miR -21, -106a, -155 (up); miR-126, -199a, -335
(down)
[96]
Whole blood miR-195 (up) miR-21, -10b (up) in ER -ve patients; let-7a
(down) in lymph node +ve patients
[97]
Serum miR-21 (up) correlated with visceral metastasis [98]
Non-small-cell
lung carcinoma
Pooled serum miR-25, -223 (up) [99]
Exosome
from plasma
miR-17-3p, -21, -106a, -146, -155, -191, -192, -203,
-205, -210, -212, -214 (up)
[58]
Pooled serum miR-486, -30d (up); miR-1, -499 (down)
associated with overall survival
[100]
Serum miR-10b, -155 (up) miR-10b (up) associated with lymph node
metastasis
[101]
Vesicles of
plasma
samples
let-7d, let-7f, miR-223, -383, -192, -30e-5p, -301, -572,
-20b, -345 (down)
let-7f, miR-30e-3p (up) associated with poor
outcome
[59]
Gastrointestinal Cancers
Colorectal
cancer
Plasma miR-17-3p, -92 (up) [102]
Plasma miR-29a, -92a (up) [103]
Plasma miR-221 (up) miR-221 (up) associated with poor overall
survival
[104]
Esophageal Serum miR-10a, -22, -100, -148b, -223, -133a, -127-3p (up) [105]
Gastric cancer Serum miR-1, -20a, -27a, -34, -423-5p (up) miR-1, -20a, -27a, -34, -423-5p (up) [106]
Plasma miR-17-5p, -21, -106a, -106b (up); let-7a (down) [107]
Hepatocellu-lar
carcinoma
Serum miR-500 (up) [108]
Serum miR-1, -25, -92a, -206, -375, -let-7f (up) (HBV-
associated); miR-25, -375, and let-7f (up) (HCC
detection)
[109]
Serum miR-21, -122, -223 (up) [110]
Serum miR-122 (up) [111]
Serum miR-885-5p (up) [112]
Serum miR-16 (down) combined with AFP, AFP DCP
increases specificity of HCC detection
[113]
Pancreatic
cancer
Plasma miR-21, -210, -155, -196a (up) [63]
Plasma miR-210 (up) [62]
Plasma miR-21 (up) [60]
Serum miR-21, -155, -196a (up) miR-196a (up) [61]
Ovarian cancer Exosome
from serum
miR-21, -141, -200a, -200c, -200b, -203, -205, -214
(up) correlated with stage
miR-21, -141, -200a, -200c, -200b, -203, -205,
-214 (up) correlated with stage
[57]
Serum miR-21, -92, -93, -126 -29a (up); miR-155, -127, -99b
(down)
[64]
Whole blood miR-30c1* (up); miR -342-3p, -181a*, -450b-5p
(down)
[114]
Hui et al. BMC Cancer 2011, 11:500
http://www.biomedcentral.com/1471-2407/11/500
Page 4 of 9“wirings” in human cancers [51], wherein just as four
distinct mRNA profiles can all predict for breast cancer
relapse [52], a similar phenomenon might also apply to
miR profiles, although this remains to be definitively
proven.
Micro-RNAs in blood samples
There is emerging interest in the investigation of miRs
as non-invasive biomarkers in circulating blood. This
was first described in B-cell lymphoma, reporting ele-
vated levels of miR-155, -210 and -21 in patients’ sera,
with miR-21 associating with relapse-free survival [53].
In epithelial cancers, Mitchell et al.f i r s ti d e n t i f i e d
tumor-derived miRs in plasma samples, and suggested
that variations in miR abundance reflected tumor bur-
den [54]. MiRs have been detected as free miRs in either
plasma or serum, or contained within microvesicles such
as exosomes; the latter being minute, natural membrane
vesicles secreted by a variety of different cell types [55].
In addition to miRs, exosomes also carry intact and
functional mRNA [56], with the probable purpose of
transferring information and signals throughout the
body [55]. Association of epithelial cancer and exosome
miRs was first illustrated in ovarian cancer, wherein
tumor-derived miR profiles strongly correlated with
levels of peripheral blood-derived exosomal miRs [57].
Similar observations have also been reported for lung
cancer [58,59].
As shown in Table 2, the list of potential blood miR
biomarkers is even more diverse than those from tissue
studies (Table 1). The greatest degree of overlap was
reported for miR-21, miR-196a and miR-210 from four
different pancreatic cancer studies [60-63]. As observed
for the tissue studies, miR-21 and miR-155 are also the
two most common aberrant miRs in circulation with
putative diagnostic and prognostic value (Table 2). How-
ever, down-regulation of miR-155 was reported in one
serum study of ovarian cancer [64]. There is some con-
troversy surrounding miR-155; the majority of reports
suggest an oncogenic role; however, in a lung cancer
study, its up-regulation predicted for worse outcome for
adenocarcinomas, but improved outcome for squamous
cell carcinoma patients [65]. One possible tumor sup-
pression function for miR-155 was demonstrated in
miR-155 deficient mice, which appeared to reduce onco-
genic translocations generated by activation-induced
cytidine deaminase (AICD) [66]. Micro-RNA expression
levels in circulation can also relate to hormone receptor
status in that estrogen negative breast cancer sera sam-
ples had higher levels of miR-21 and miR-10b [67]; in
contrast. miR-155 was detected for progesterone recep-
tor positive patients [68].
In summary, there are multitudes of reports describing
the potential value of miRs as both diagnostic and prog-
nostic bio-markers for human malignancies. None to
date, however, have been translated into clinical prac-
tice, likely a reflection of its complex biology, and lack
of validation studies using appropriately-powered sample
sizes.
Challenges of Micro-RNA as bio-markers
Despite the promising data supporting the potential value
of miRs as biomarkers, many challenges remain. First,
robust platforms, as well as appropriate statistical and
bio-computational analyses must be utilized in order to
identify potential candidate miR signatures for predicting
outcome. Furthermore, such candidate signatures must
be validated using independent cohorts statistically pow-
ered to confirm the existence of a predictive signature.
Second, the selection of the appropriate reference con-
trols is extremely important for normalization of biologi-
cal variation. Recent reports have observed that some of
the commonly-utilized reference miRs, such as RNU43,
RNU44 or RNU48, in fact fluctuate with the biological
entity of interest [69]; hence it is critical to determine the
most stable miRs for each condition under examination.
Third, it is conceivable that given the “upstream” effects
of miRs, and their biological complexities which we are
just starting to unravel, their pattern of expression might
be too subtle and variable to serve as robust predictive
signatures. Nonetheless, pursuit of investigations such as
prognostic signatures, or their measurements in sera/
plasma are definitely warranted, particularly when using
appropriately-sized population cohorts.
Table 2 Micro-RNAs as Non-invasive Biomarkers in Blood Samples (Continued)
Prostate cancer Serum miR-141 (up) miR-100, -125b, -141, -143, -296 (up) [54]
Serum miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p,
-486-5p, -92b, -574-3p, -636, -640, -766, -885-5p (up)
[115]
Serum miR-20b, -874, -1274a, -1207-5p, -93, -106a (up); miR-
223, -26b, -30c, -24 (down)
miR-24 (down) in metastatic cancers [116]
Serum miR-375, -141 (up) miR-375, -141 (up) [117]
Serum miR-21 (up) miR-21 (up) associated with resistant to
docetaxel-based chemotherapy
[118]
Serum miR-21, -141, -221 (up) miR-21, -141, -221 (up) [119]
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Application of the potential role of miRs as molecular
bio-markers in human epithelial malignancies is widely
supported by the large number of studies conducted in
different cancers. There is great promise that they will
aid in the early diagnosis of cancer, and the develop-
ment of personalized therapies. Further research into
miR biogenesis and regulation, along with functional
target identifications will definitely lead to an improved
understanding of the complex mechanisms underlying
human cancer development and progression.
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